Tag: units

TORONTO, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company dedicated to developing innovative therapeutics for critical medical needs, announces that it has closed the first tranche of its previously announced private placement offering (the “Offering”). The first tranche of the Offering consisted of the issuance of 2,900,000 units of the Company (each, a “Unit”), at a price of $0.021 per Unit, for total gross proceeds to Revive of $60,900. Furthermore, the Company announces that it has settled an amount of $67,400 owing pursuant to an arm’s length note through the issuance of 3,209,523 Units, at a price of $0.021 per Unit, being the same issue price and security offered pursuant to the Offering.

NEEDHAM, Mass, Aug. 11, 2025 (GLOBE NEWSWIRE) -- McKinley Acquisition Corporation (the “Company”), announced the pricing of its initial public offering of 15,000,000 units at $10.00 per unit, with each unit consisting of one Class A ordinary share and one right. Each right entitles the holder to receive one-tenth (1/10) of one Class A ordinary share upon consummation of the Company’s initial business combination. The units are expected to trade on the Nasdaq Global Market (“Nasdaq”) under the symbol “MKLYU” beginning on August 12, 2025. Once the securities comprising the units begin separate trading, the Class A ordinary shares and rights will be traded on Nasdaq under the symbols “MKLY” and “MKLYR,” respectively.

Strong operating results following a strategic transition to a pure-play industrial REIT

Increases 2025 Adjusted EBITDA Guidance

- Q2 Total Revenue up 10% YoY to $102.9 Million -
- Q2 Net Income Increases to $8.2 Million or $0.19 Earnings per Share –
- Q2 Operating Cash Flow of $11.4 Million -
- Q2 Adjusted EBITDA increases to $3.4 Million -